While many of these issues are applicable to other parts of the industry, Cambridge Healthtech Institute (CHI) hosted a panel ...

Athira Pharma will cut about 49 positions, including two people in the C-suite. The announcement follows the company’s ...

A lawsuit filed by the Pharmaceutical Research and Manufacturers of America, which claims the Inflation Reduction Act’s ...

As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug, BioSpace takes a closer look at the ...

With an FDA action date of Sept. 26, Bristol Myers Squibb’s KarXT could soon be the first new type of schizophrenia drug in ...

Bristol Myers Squibb is continuing its cost-savings measures with layoffs in Lawrenceville, New Jersey. The company announced ...

Monday’s failure to improve overall survival in breast cancer “further dents belief” in the companies’ Dato-DXd and “likely ...

An unusual placebo effect in Aligos Therapeutics’ Phase IIa trial is driving shareholder skepticism for its metabolic ...

Novo Nodrisk’s cannabinoid receptor–targeting obesity pill was picked up in the $1.1 billion acquisition of Inversago ...

D Molecular Therapeutics reported its experimental gene therapy demonstrated a nearly 90% reduction in the need for ...

If Johnson & Johnson refuses to scrap its proposed changes to the 340B drug pricing for hospitals, it risks the termination ...

The positive readout in patients with non-relapsing secondary progressive multiple sclerosis comes on the heels of ...